CD22 is an inclusion criterion in 22 clinical trials for B-cell acute lymphoblastic leukemia, of which 22 are open and 0 are closed. Of the trials that contain CD22 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (2 open), 10 are phase 1 (10 open), 4 are phase 1/phase 2 (4 open), 4 are phase 2 (4 open), 1 is phase 3 (1 open), and 1 is phase 4 (1 open) [4].

CD22 is an inclusion criterion in 10 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 3 are closed. Of the trials that contain CD22 status and acute lymphoblastic leukemia as inclusion criteria, 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [4].

CD22 is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain CD22 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), and 1 is phase 1/phase 2 (0 open) [4].

CD22 is an inclusion criterion in 4 clinical trials for hairy cell leukemia, of which 3 are open and 1 is closed. Of the trials that contain CD22 status and hairy cell leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

CD22 is an inclusion criterion in 4 clinical trials for leukemia, of which 4 are open and 0 are closed. Of the trials that contain CD22 status and leukemia as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

CD22 is an inclusion criterion in 4 clinical trials for lymphoma, of which 4 are open and 0 are closed. Of the trials that contain CD22 status and lymphoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

CD22 is an inclusion criterion in 4 clinical trials for transformed non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain CD22 status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [4].

CD22 is an inclusion criterion in 3 clinical trials for B-cell lymphoblastic lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CD22 status and B-cell lymphoblastic lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

CD22 is an inclusion criterion in 3 clinical trials for chronic myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain CD22 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

CD22 is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CD22 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 1 is phase 1/phase 2 (1 open) [4].

CD22 is an inclusion criterion in 3 clinical trials for hairy cell leukemia variant, of which 3 are open and 0 are closed. Of the trials that contain CD22 status and hairy cell leukemia variant as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

CD22 is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain CD22 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

CD22 is an inclusion criterion in 3 clinical trials for primary mediastinal B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CD22 status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 1 (2 open) [4].

CD22 is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 2 are open and 0 are closed. Of the trials that contain CD22 status and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 2 are phase 1 (2 open) [4].

CD22 is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain CD22 status and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open) [4].

CD22 is an inclusion criterion in 2 clinical trials for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain CD22 status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open) [4].

CD22 is an inclusion criterion in 2 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CD22 status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and B-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and B-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains CD22 status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for Burkitt leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and Burkitt leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

CD22 is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains CD22 status and Richter syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].